0001127602-19-006088.txt : 20190214 0001127602-19-006088.hdr.sgml : 20190214 20190214181741 ACCESSION NUMBER: 0001127602-19-006088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190212 FILED AS OF DATE: 20190214 DATE AS OF CHANGE: 20190214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McKenzie Paul CENTRAL INDEX KEY: 0001677903 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 19608999 MAIL ADDRESS: STREET 1: BIOGEN INC. STREET 2: 225 BINNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-02-12 0000875045 BIOGEN INC. BIIB 0001677903 McKenzie Paul BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 1 EVP Pharmaceutical Oper & Tech Common Stock 2019-02-12 4 M 0 1263 0 A 5639.631 D Common Stock 2019-02-12 4 F 0 380 319.43 D 5259.631 D Common Stock 2019-02-12 4 M 0 1799 0 A 7058.631 D Common Stock 2019-02-12 4 F 0 539 319.43 D 6519.631 D Restricted Stock Unit 0 2019-02-12 4 M 0 1263 0 D 2020-02-12 Common Stock 1263 2527 D Restricted Stock Unit 0 2019-02-12 4 M 0 1799 0 D 2021-02-12 Common Stock 1799 7671 D Restricted Stock Unit 0 2019-02-12 4 J 0 1357 0 D 2021-02-12 Common Stock 1357 6314 D Restricted Stock Unit 0 2019-02-12 4 A 0 10960 0 A 2022-02-12 Common Stock 10960 10960 D Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018. The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. /s/ Suzanne Murray, Attorney in Fact for Paul McKenzie 2019-02-14